Comparative Pharmacology
Head-to-head clinical analysis: THIORIDAZINE HYDROCHLORIDE INTENSOL versus THORAZINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: THIORIDAZINE HYDROCHLORIDE INTENSOL versus THORAZINE.
THIORIDAZINE HYDROCHLORIDE INTENSOL vs THORAZINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thioridazine is a typical antipsychotic of the phenothiazine class. It blocks dopamine D2 receptors in the brain, particularly in the mesolimbic pathway, and also exhibits antagonism at alpha-adrenergic, histaminergic H1, and muscarinic M1 receptors.
Antagonist at dopamine D2 receptors in the mesolimbic pathway; also blocks alpha-adrenergic, histaminergic, and muscarinic receptors.
50 mg orally twice daily initially, titrated to 200-800 mg/day in divided doses. Maximum 800 mg/day.
10-25 mg orally 3-4 times daily; maximum 800 mg/day. 25-50 mg intramuscularly every 4-6 hours.
None Documented
None Documented
Terminal elimination half-life ranges from 21 to 30 hours (mean 24 h). In elderly or patients with hepatic impairment, half-life may be prolonged. Requires multiple days to reach steady state.
Terminal elimination half-life: 15–30 hours (mean ~24 h); may extend to 40+ h in elderly or hepatic impairment.
Primarily hepatic metabolism with <1% excreted unchanged in urine; metabolites eliminated in bile and feces. Approx. 30–40% of a dose appears in urine as metabolites (mostly sulfoxides and side-chain oxidized products) and 50–60% in feces.
Renal (biliary/fecal): ~70% renal as metabolites, ~30% biliary/fecal; <1% unchanged in urine.
Category A/B
Category C
Typical Antipsychotic
Typical Antipsychotic